Neuroone Medical Technologies CORP 8-K filings

NeuroOne Medical Technologies Corporation announced increased product revenue and reduced operating expenses in its third quarter fiscal year 2024 results, alongside key advancements in its product pipeline.

NeuroOne Medical Technologies Corporation has successfully raised $2.65 million through a private placement and secured a $3 million debt facility to fund operations and product development.

NeuroOne Medical Technologies Corporation has received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, placing it at risk of delisting.

NeuroOne Medical Technologies Corporation has amended its bylaws, reducing the quorum requirement for stockholder meetings and updating rules for director nominations.

NeuroOne Medical Technologies Corporation announced a significant increase in product revenue and advancements in its key programs for the second quarter of fiscal year 2024.

NeuroOne Medical Technologies Corporation has commenced a limited commercial launch of its OneRF Ablation System, marking the first thin-film, sEEG-guided RF system capable of both recording electrical activity and ablating nervous tissue with temperature control.

NeuroOne Medical Technologies held its annual meeting, electing a director, ratifying its auditor, and approving executive compensation, while also providing a corporate update including a new presentation.

NeuroOne Medical Technologies Corporation announced a significant increase in product revenue and FDA clearance for its OneRF Ablation System in its first quarter fiscal year 2024 results.